Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review
Publication date: Available online 28 November 2020Source: Journal of Pharmaceutical AnalysisAuthor(s): Sara Meirinho, Márcio Rodrigues, Ana Fortuna, Amílcar Falcão, Gilberto Alves (Source: Journal of Pharmaceutical Analysis)
Source: Journal of Pharmaceutical Analysis - November 28, 2020 Category: Drugs & Pharmacology Source Type: research
Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review.
Abstract
Lennox-Gastaut syndrome (LGS) is a childhood-onset epileptic encephalopathy characterized by multiple types of medically intractable seizures, cognitive impairment, and generalized slow spike-wave discharges in electroencephalography (EEG). Although the onset of this epileptic syndrome occurs typically before eight years of age with a peak age between 3 and 5 years, lifelong persistence of the syndrome is usual. The evolution of clinical features, EEG findings, and paucity of knowledge about LGS among adult health care providers can make LGS significantly underdiagnosed in the adult population. ...
Source: Epilepsy and Behaviour - November 23, 2020 Category: Neurology Authors: Samanta D Tags: Epilepsy Behav Source Type: research
Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox–Gastaut syndrome: A prospective observational clinical study
Publication date: November 2020Source: Epilepsy & Behavior, Volume 112Author(s): Francesca Felicia Operto, Alberto Verrotti, Alfonso Marrelli, Roberta Ciuffini, Giangennaro Coppola, Grazia Maria Giovanna Pastorino, Pasquale Striano, Michela Sole, Claudio Zucca, Valentina Manfredi, Santina Città, Maurizio Elia (Source: Epilepsy and Behavior)
Source: Epilepsy and Behavior - September 11, 2020 Category: Neurology Source Type: research
Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: A prospective observational clinical study.
CONCLUSION: Adjunctive treatment with RFM did not negatively affect cognitive, adaptive function, and emotional profile in patients with LGS after 1 year of follow-up.
PMID: 32920379 [PubMed - as supplied by publisher] (Source: Epilepsy and Behaviour)
Source: Epilepsy and Behaviour - September 9, 2020 Category: Neurology Authors: Operto FF, Verrotti A, Marrelli A, Ciuffini R, Coppola G, Pastorino GMG, Striano P, Sole M, Zucca C, Manfredi V, Città S, Elia M Tags: Epilepsy Behav Source Type: research
The Toxicity of Newer and Lesser-Known Anticonvulsant Drugs
AbstractPurpose of ReviewThis review describes newer and lesser-known anticonvulsant drugs. Due to increased diagnostic accuracy of seizure disorder subtypes, as well as escalating off-label and experimental usage, these agents are becoming more commonplace. Important mechanisms of action, pharmacokinetics/pharmacodynamics, critical medication interactions, adverse reactions, toxicities, and treatment strategies are discussed.Recent FindingsCenobamate, clobazam, eslicarbazepine, ethosuximide, everolimus, felbamate, lacosamide, perampanel, methsuximide, levetiracetam (and the related compound brivaracetam), rufinamide, stir...
Source: Current Emergency and Hospital Medicine Reports - August 21, 2020 Category: Emergency Medicine Source Type: research
Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Abstract
Lennox-Gastaut syndrome (LGS) is a severe developmental epileptic encephalopathy diagnosed in childhood that persists through adolescence and into adulthood. While the characteristics of LGS in pediatric patients are well defined, including "drop attacks", interictal slow spike and wave electroencephalogram (EEG) activity, and intellectual disability, these features can evolve over time, and different EEG activities may be present in adult patients with LGS. This may result in missed diagnoses in these patients and subsequent challenges for the adequate treatment of their seizures. Based on discus...
Source: Epilepsy and Behaviour - June 17, 2020 Category: Neurology Authors: Montouris G, Aboumatar S, Burdette D, Kothare S, Kuzniecky R, Rosenfeld W, Chung S Tags: Epilepsy Behav Source Type: research
Improving the dissolution of a water-insoluble orphan drug through a fused deposition modelling 3-dimensional printing technology approach.
IMPROVING THE DISSOLUTION OF A WATER-INSOLUBLE ORPHAN DRUG THROUGH A FUSED DEPOSITION MODELLING 3-DIMENSIONAL PRINTING TECHNOLOGY APPROACH.
Eur J Pharm Sci. 2020 Jun 13;:105426
Authors: Saydam M, Takka S
Abstract
Lennox-Gastaut Syndrome (LGS) is a rare form of childhood epilepsy. Rufinamide is an orphan drug indicated for the treatment of LGS. Three-Dimensional Printing (3DP) is a process in which solid objects are created based on a digital file by adding materials layer by layer. Fused deposition modelling (FDM) is a 3DP technique with the advantages of solid dispersion systems ...
Source: European Journal of Pharmaceutical Sciences - June 12, 2020 Category: Drugs & Pharmacology Authors: Saydam M, Takka S Tags: Eur J Pharm Sci Source Type: research
Lennox-Gastaut syndrome: New treatments and treatments under investigation.
Authors: Auvin S
Abstract
There are currently five compounds (clobazam, felbamate, lamotrigine, topiramate, rufinamide) available for prescription with a demonstrated efficacy on drop seizures for Lennox-Gastaut syndrome (LGS). There are also currently new and under-investigation compounds. This paper gives an overview on these novel developments for LGS based on the lecture given at the French Chapter meeting of the International League Against Epilepsy (ILAE) held in Paris in October 2019. Five compounds were discussed. Epidiolex (cannabidiol) has been approved recently based on positive randomized contr...
Source: Revue Neurologique - May 17, 2020 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox–Gastaut syndrome: A study of 34 patients
Publication date: July 2020Source: Epilepsy & Behavior, Volume 108Author(s): Roberto H. Caraballo, Juan Pociecha, Gabriela Reyes, Alberto Espeche, Santiago Galichio, Lorena Fasulo, Marcos Semprino (Source: Epilepsy and Behavior)
Source: Epilepsy and Behavior - April 24, 2020 Category: Neurology Source Type: research
Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
CONCLUSION: Rufinamide may be used as a treatment option in DEE and REP other than LGS.
PMID: 32334364 [PubMed - as supplied by publisher] (Source: Epilepsy and Behaviour)
Source: Epilepsy and Behaviour - April 21, 2020 Category: Neurology Authors: Caraballo RH, Pociecha J, Reyes G, Espeche A, Galichio S, Fasulo L, Semprino M Tags: Epilepsy Behav Source Type: research
Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review
(Source: Neuropsychiatric Disease and Treatment)
Source: Neuropsychiatric Disease and Treatment - February 4, 2020 Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program
ConclusionThese analyses suggest that concomitant to CBD, AEDs may not have an effect on reducing seizure frequency and severity in patients with TRE. (Source: Epilepsy and Behavior)
Source: Epilepsy and Behavior - August 2, 2019 Category: Neurology Source Type: research
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
CONCLUSION: These analyses suggest that concomitant to CBD, AEDs may not have an effect on reducing seizure frequency and severity in patients with TRE.
PMID: 31382177 [PubMed - as supplied by publisher] (Source: Epilepsy and Behaviour)
Source: Epilepsy and Behaviour - July 31, 2019 Category: Neurology Authors: Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, Szaflarski JP, UAB CBD Program Tags: Epilepsy Behav Source Type: research
LC-MS/MS-Based Quantification of 9 Antiepileptic Drugs From a Dried Sample Spot Device
Conclusions:
The application of the LC-MS/MS method allowed the authors to obtain a very specific, sensitive, and rapid (total runtime = 10.3 minutes) quantification of 9 AEDs starting from very low volumes of plasma samples. The main advantage of DPS over wet samples is room temperature storage and shipment, which lowers shipment costs and makes it suitable for routine TDM. Moreover, in comparison with other alternative matrices, DPS allows for the use of the same therapeutic ranges on which routine TDM is based. DPS on DSSD can thus be considered as a useful and cheap tool for the broader application of TDM. (Source: T...
Source: Therapeutic Drug Monitoring - May 14, 2019 Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications.
CONCLUSIONS: Although allergic reactions to AEDs are rare, they are of significance because they can cause life-threatening severe cutaneous drug reactions. Therefore, patients receiving AEDs, especially aromatic AEDs, must be monitored closely. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Antiepileptic Drugs: An Analysis of the US Food and Drug Administration Adverse Event Reporting System Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Epilepsia. 2018;59(12):2318-2324.
OBJECTIVE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare and potentially fatal adverse sk...
Source: Epilepsy Currents - April 10, 2019 Category: Neurology Tags: Epilepsy Curr Source Type: research
